1. "Genitourinary Oncology Service"
Formats
  1. Journal Article (2745)
  2. Meeting Abstract (2507)
  3. Review (113)
  4. Book Section (82)
  5. Editorial (52)
  6. Correspondence (33)
  7. Conference Paper (29)
  8. Guidelines (24)
  9. Research Letter (15)
  10. Book Whole (4)
  11. Miscellaneous (4)
Groups
  1. Genitourinary Oncology Service (5608)
  2. Solid Tumor Oncology Division (5608)
  3. Department of Medicine (5598)
  4. GSK Faculty (1640)
  5. Human Oncology and Pathogenesis Program (1139)
  6. Department of Pathology and Laboratory Medicine (1034)

More Groups

People
  1. Robert Motzer (1243)
  2. Howard Scher (1130)
  3. David Solit (779)
  4. Dean Bajorin (657)
  5. Michael Morris (577)
  6. Jonathan Rosenberg (510)

More People

Years
  1. 2025 (118)
  2. 2024 (293)
  3. 2023 (283)
  4. 2022 (314)
  5. 2021 (341)
  6. 2020 (352)

More Years

Publications
  1. Journal of Clinical Oncology (1697)
  2. Annals of Oncology (303)
  3. Clinical Cancer Research (282)
  4. Cancer Research (245)
  5. Cancer (125)
  6. European Urology (118)

More Publications

Publishers
  1. American Society of Clinical Oncology (1757)
  2. American Association for Cancer Research (688)
  3. Oxford University Press (408)
  4. Elsevier Science, Inc. (389)
  5. Elsevier Inc. (384)
  6. Nature Publishing Group (294)

More Publishers

Results (5608)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Phase 2, multicenter, open-label basket trial of nab-sirolimus for patients with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes (PRECISION I)
    Meeting Abstract

    Iyer, G.; Demeure, M. J.; Deming, D. A.; Federman, N.; McKean, M.; Lee, E. K.; Spira, A. I.; Kwiatkowski, D. J.; Hussein, M. A.; Gordon, E. M.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Phase 2 clinical study evaluating the efficacy and safety of disitamab vedotin with or without pembrolizumab in patients with HER2-expressing urothelial carcinoma (RC48G001)
    Meeting Abstract

    Powles, T.; Yu, E. Y.; Iyer, G.; Campbell, M. T.; Loriot, Y.; De Santis, M.; O'Donnell, P. H.; Burgess, E. F.; Necchi, A.; Krieger, L. E. M.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Phase 3 LITESPARK-022: Pembrolizumab (pembro) plus hypoxia-inducible factor 2α (HIF-2α) inhibitor belzutifan as adjuvant treatment for clear cell renal cell carcinoma (ccRCC)
    Meeting Abstract

    Choueiri, T. K.; Bedke, J.; Karam, J. A.; McKay, R. R.; Motzer, R. J.; Pal, S. M.; Suárez, C.; Uzzo, R.; Liu, H.; Burgents, J. E.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • P3BEP (ANZUP 1302): An international randomized phase 3 trial of accelerated versus standard BEP chemotherapy for male and female adults and children with intermediate- and poor-risk metastatic germ cell tumours (GCTs)
    Meeting Abstract

    Zebic, D.; Stockler, M. R.; Martin, A. J.; Pashankar, F. D.; Tran, B.; Mazhar, D.; Huddart, R. A.; Wheater, M.; Walpole, E. T.; Dunwoodie, E.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Alliance A032002 (ART): Phase II randomized trial of atezolizumab versus atezolizumab and radiation therapy for platinum-ineligible/refractory metastatic urothelial cancer
    Meeting Abstract

    Nagar, H.; Ballman, K. V.; Tagawa, S. T.; Tan, A.; Faltas, B. M.; Sheybani, A.; Baghaie, S.; Schwartz, L. H.; Kozono, D. E.; Bogart, J. A.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • A phase II trial of intravesical chemoimmunotherapy with gemcitabine and bacillus Calmette-Guérin (BCG) for patients with BCG-exposed, high-grade, non-muscle–invasive bladder cancer
    Meeting Abstract

    Gaffney, C.; Dsouza, N.; Hernandez, C.; McCarter, M.; Moran, P.; Stasi, K.; Worth, K.; Dalbagni, G.; Donahue, T. F.; Donat, S. M.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • A phase II trial modifying metabolic syndrome and cardiovascular risk for patients with prostate cancer on ADT using a risk factor modification program and continuous Fitbit monitoring (ProTrio)
    Meeting Abstract

    Hahn, A. W.; Slack Tidwell, R.; Thoman, W.; Abdulla, A.; Koutroumpakis, E.; Aparicio, A.; Subudhi, S. K.; Siddiqui, B. A.; Pilié, P. G.; Zurita, A. J.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Alliance A031902 (CASPAR): A randomized phase (ph) 3 trial of enzalutamide with rucaparib/placebo in first-line metastatic castration-resistant prostate cancer (mCRPC)
    Meeting Abstract

    Rao, A.; Heller, G.; Ryan, C. J.; VanderWeele, D. J.; Lewis, L. D.; Tan, A.; Watt, C.; Chen, R. C.; Kohli, M.; Barata, P. C.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • A phase 2 study of immunogenic cell death inducer PT-112 in patients with metastatic castration-resistant prostate cancer
    Meeting Abstract

    Bryce, A. H.; Karp, D. D.; Tagawa, S. T.; Nordquist, L. T.; Rathkopf, D. E.; Adra, N.; Dorff, T. B.; Baeck, J.; O'Donnell, J. F.; Ames, T. D.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Pembrolizumab (pembro) monotherapy for patients (pts) with high-risk non–muscle-invasive bladder cancer (HR NMIBC) unresponsive to bacillus Calmette–Guérin (BCG): Results from cohort B of the phase 2 KEYNOTE-057 trial
    Meeting Abstract

    Necchi, A.; Roumiguié, M.; Esen, A. A.; Lebret, T.; De Wit, R.; Shore, N. D.; Bajorin, D. F.; Krieger, L. E. M.; Kandori, S.; Uchio, E. M.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save